Samsung BioLogics, parent company of the biosimilar development business Samsung Bioepis, has been fined by the Republic of Korea’s financial regulatory body, The Securities and Futures Commission, after the commission ruled that Samsung had committed fraud.
Samsung BioLogics, parent company of the biosimilar development business Samsung Bioepis, has been fined by the Republic of Korea’s financial regulatory body, The Securities and Futures Commission, after the commission ruled that Samsung had committed fraud.
As reported by Nikkei Asian Review, the commission found that, in 2015, Samsung BioLogics used accounting methods that inflated the value of Samsung Bioepis ahead of an initial public offering in 2016.
In addition to imposing a fine of approximately $7.05 million and suspending Samsung BioLogics’ trading, the commission could also recommend that the company be delisted from the Korean stock exchange. Such a delisting would have major impacts on the company; currently, says Korea Times, Samsung Biologics is Korea’s fifth largest firm in terms of market capitalization.
In a letter to shareholders, Samsung BioLogics defended itself, saying, “Samsung BioLogics would like to sincerely apologize to our clients and shareholders for the confusion caused by the recent accounting issue. However, the SFC's announcement today is very unfortunate as it is our firm belief that Samsung BioLogics has not breached any accounting rules at all.”
The company went on to indicate that it sought the advice of multiple accounting firms, all of whom deemed its accounting practices acceptable. Furthermore, the company said that it plans to file a lawsuit to “clearly prove the legality of Samsung BioLogics’ actions.”
News of the scandal and its repercussions come shortly on the heels of reports that Biogen has increased its stake in Samsung Bioepis. Earlier this month, Samsung BioLogics confirmed that it will conclude a transfer of shares to Biogen that has been pending since June of this year. Under the deal, Biogen will receive more than 9 million shares of the joint venture for a payment of approximately $677 million.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.